Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

Clicks: 217
ID: 82215
2018
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.
Reference Key
fusco2018osteonecrosisdentistry Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Fusco, Vittorio;Campisi, Giuseppina;Boissieu, Paul de;Monaco, Federico;Baraldi, Anna;Numico, Gianmauro;Bedogni, Alberto;
Journal dentistry journal
Year 2018
DOI DOI not found
URL
http://www.mdpi.com/2304-6767/6/3/42
Keywords
Medicine Dentistry neoplasms. tumors. oncology. including cancer and carcinogens public aspects of medicine diseases of the respiratory system internal medicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.